Zoetis’ (ZTS) “Buy” Rating Reaffirmed at Jefferies Group LLC

Jefferies Group LLC reiterated their buy rating on shares of Zoetis Inc. (NYSE:ZTS) in a research note released on Friday morning. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.

ZTS has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Cantor Fitzgerald restated a buy rating and issued a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a hold rating to a sell rating in a report on Friday, October 6th. Morgan Stanley lifted their price objective on shares of Zoetis from $61.00 to $70.00 and gave the company an equal weight rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $67.06.

Shares of Zoetis (NYSE:ZTS) opened at $68.88 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market cap of $33,686.24, a PE ratio of 31.71, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zoetis has a 12-month low of $48.24 and a 12-month high of $70.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 earnings per share. equities research analysts anticipate that Zoetis will post 2.36 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/14/zoetis-zts-buy-rating-reaffirmed-at-jefferies-group-llc.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be given a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.61%. Zoetis’s dividend payout ratio is presently 22.11%.

Hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its position in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Harfst & Associates Inc. raised its position in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in Zoetis in the 2nd quarter valued at $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Peddock Capital Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at $140,000. Hedge funds and other institutional investors own 92.44% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply